166 related articles for article (PubMed ID: 33971670)
21. Identification of significant genes as prognostic markers and potential tumor suppressors in lung adenocarcinoma via bioinformatical analysis.
Lu M; Fan X; Liao W; Li Y; Ma L; Yuan M; Gu R; Wei Z; Wang C; Zhang H
BMC Cancer; 2021 May; 21(1):616. PubMed ID: 34039311
[TBL] [Abstract][Full Text] [Related]
22. A qualitative transcriptional signature to reclassify histological grade of ER-positive breast cancer patients.
Li J; Jiang W; Liang Q; Liu G; Dai Y; Zheng H; Yang J; Cai H; Zheng G
BMC Genomics; 2020 Apr; 21(1):283. PubMed ID: 32252627
[TBL] [Abstract][Full Text] [Related]
23. Systemic analyses of expression patterns and clinical features for GIMAPs family members in lung adenocarcinoma.
Deng S; Zhang Z; Lu X; Zhou Q; Xia S; Li M
Aging (Albany NY); 2020 Oct; 12(20):20413-20431. PubMed ID: 33115964
[TBL] [Abstract][Full Text] [Related]
24. High expression of CXCL14 is a biomarker of lung adenocarcinoma with micropapillary pattern.
Sata Y; Nakajima T; Fukuyo M; Matsusaka K; Hata A; Morimoto J; Rahmutulla B; Ito Y; Suzuki H; Yoshino I; Kaneda A
Cancer Sci; 2020 Jul; 111(7):2588-2597. PubMed ID: 32403160
[TBL] [Abstract][Full Text] [Related]
25. Exploring exosome data to identify prognostic gene signatures for lung adenocarcinoma.
Li J; Gao X; Tian S; Tang M; Liu W
Future Oncol; 2021 Dec; 17(34):4745-4756. PubMed ID: 34658257
[TBL] [Abstract][Full Text] [Related]
26. Identification of prognostic genes through expression differentiation during metastatic process in lung adenocarcinoma.
An N; Yang X
Sci Rep; 2017 Sep; 7(1):11119. PubMed ID: 28894185
[TBL] [Abstract][Full Text] [Related]
27. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
28. Genome-scale analysis to identify prognostic markers and predict the survival of lung adenocarcinoma.
Li YY; Yang C; Zhou P; Zhang S; Yao Y; Li D
J Cell Biochem; 2018 Nov; 119(11):8909-8921. PubMed ID: 30105759
[TBL] [Abstract][Full Text] [Related]
29. Molecular characterization of lung adenocarcinoma: A potential four-long noncoding RNA prognostic signature.
Sui J; Yang S; Liu T; Wu W; Xu S; Yin L; Pu Y; Zhang X; Zhang Y; Shen B; Liang G
J Cell Biochem; 2019 Jan; 120(1):705-714. PubMed ID: 30125988
[TBL] [Abstract][Full Text] [Related]
30. Prognostic and Chemotherapy Predictive Value of Gene-Expression Phenotypes in Primary Lung Adenocarcinoma.
Ringnér M; Jönsson G; Staaf J
Clin Cancer Res; 2016 Jan; 22(1):218-29. PubMed ID: 26265693
[TBL] [Abstract][Full Text] [Related]
31. High kinesin family member 18A expression correlates with poor prognosis in primary lung adenocarcinoma.
Li X; Liu M; Zhang Z; Zhang L; Liang X; Sun L; Zhong D
Thorac Cancer; 2019 May; 10(5):1103-1110. PubMed ID: 30907518
[TBL] [Abstract][Full Text] [Related]
32. Bioinformatics and survival analysis of glia maturation factor-γ in pan-cancers.
Lan A; Ren C; Wang X; Tong G; Yang G
BMC Cancer; 2021 Apr; 21(1):423. PubMed ID: 33863293
[TBL] [Abstract][Full Text] [Related]
33. Differential
Lin S; Tian C; Li J; Liu B; Ma T; Chen K; Gong W; Wang JM; Huang J
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33786615
[TBL] [Abstract][Full Text] [Related]
34. Microarray analysis of the expression profile of immune-related gene in rapid recurrence early-stage lung adenocarcinoma.
Liu J; Yang X; Zhang L; Yang B; Rao W; Li M; Dai N; Yang Y; Qian C; Zhang L; Xiao H; Wang D
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2299-2310. PubMed ID: 32556504
[TBL] [Abstract][Full Text] [Related]
35. Exosomal miRNA profiling before and after surgery revealed potential diagnostic and prognostic markers for lung adenocarcinoma.
Xue X; Wang C; Xue Z; Wen J; Han J; Ma X; Zang X; Deng H; Guo R; Asuquo IP; Qin C; Wang H; Gao Q; Liu S; Wang J
Acta Biochim Biophys Sin (Shanghai); 2020 Mar; 52(3):281-293. PubMed ID: 32073597
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of CENPF is associated with progression and poor prognosis of lung adenocarcinoma.
Li MX; Zhang MY; Dong HH; Li AJ; Teng HF; Liu AL; Xu N; Qu YQ
Int J Med Sci; 2021; 18(2):494-504. PubMed ID: 33390818
[No Abstract] [Full Text] [Related]
37. Mast cell-based molecular subtypes and signature associated with clinical outcome in early-stage lung adenocarcinoma.
Bao X; Shi R; Zhao T; Wang Y
Mol Oncol; 2020 May; 14(5):917-932. PubMed ID: 32175651
[TBL] [Abstract][Full Text] [Related]
38. Seven interferon gamma response genes serve as a prognostic risk signature that correlates with immune infiltration in lung adenocarcinoma.
Yao B; Wang L; Wang H; Bao J; Li Q; Yu F; Zhu W; Zhang L; Li W; Gu Z; Fei K; Zhang P; Zhang F; Huang X
Aging (Albany NY); 2021 Apr; 13(8):11381-11410. PubMed ID: 33839701
[TBL] [Abstract][Full Text] [Related]
39. The panoramic picture of pepsinogen gene family with pan-cancer.
Shen S; Li H; Liu J; Sun L; Yuan Y
Cancer Med; 2020 Dec; 9(23):9064-9080. PubMed ID: 33067881
[TBL] [Abstract][Full Text] [Related]
40. Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma.
Sun H; Liu SY; Zhou JY; Xu JT; Zhang HK; Yan HH; Huan JJ; Dai PP; Xu CR; Su J; Guan YF; Yi X; Yu RS; Zhong WZ; Wu YL
EBioMedicine; 2020 Oct; 60():102990. PubMed ID: 32927274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
